Saitoh H, Naitoh S, Okamoto H, Akahane Y
First Department of Internal Medicine, Yamanashi Medical College, Japan.
J Interferon Res. 1994 Oct;14(5):239-44. doi: 10.1089/jir.1994.14.239.
Patients with chronic hepatitis C were treated with interferon (IFN) and followed for hepatitis C virus (HCV) RNA and antibody to HCV (anti-HCV) in serum. The response was correlated with decrease in serum levels of HCV RNA, as well as HCV genotypes and liver histopathology. Response to IFN, estimated by clearance of HCV RNA and normalization of aminotransferase levels at 6 months after the withdrawal of IFN, was observed in 11 (31%) of 35 patients infected with HCV of genotype II/1b, 13 (72%) of 18 with genotype III/2a, and 2 (33%) of 6 with genotype IV/2b; a single patient with genotype I/1a responded while the one doubly infected with HCV of genotypes II/1b and IV/2b did not. Response was seen in 10 (71%) of 14 patients with chronic persistent hepatitis, 14 (39%) of 36 with chronic active hepatitis 2A, and 3 (27%) of 11 with 2B. Response was achieved less often in patients with high than low pretreatment levels of HCV RNA. HCV RNA dropped sharply on a day after the start of IFN, and continued to decrease during the 2 weeks, irrespective of the response to IFN or HCV genotypes. In contrast, anti-HCV decreased more gradually and only in responders to IFN. These results support the rapid development of an IFN-mediated antiviral effect on HCV, and support therapeutic effects of IFN dependent on histopathology of liver as well as HCV RNA titers and genotypes.
慢性丙型肝炎患者接受干扰素(IFN)治疗,并对其血清中的丙型肝炎病毒(HCV)RNA和抗HCV抗体(抗-HCV)进行随访。疗效与血清HCV RNA水平的降低、HCV基因型以及肝脏组织病理学相关。根据停用IFN后6个月时HCV RNA的清除情况和转氨酶水平的正常化来评估对IFN的反应,结果发现,感染II/1b基因型HCV的35例患者中有11例(31%)出现反应,感染III/2a基因型的18例患者中有13例(72%)出现反应,感染IV/2b基因型的6例患者中有2例(33%)出现反应;1例I/1a基因型患者出现反应,而1例同时感染II/1b和IV/2b基因型HCV的患者未出现反应。14例慢性持续性肝炎患者中有10例(71%)出现反应,36例慢性活动性肝炎2A患者中有14例(39%)出现反应,11例2B患者中有3例(27%)出现反应。HCV RNA治疗前水平高的患者比水平低的患者出现反应的频率更低。IFN开始治疗后的第1天,HCV RNA急剧下降,并在2周内持续降低,无论对IFN的反应或HCV基因型如何。相比之下,抗-HCV下降更为缓慢,且仅在对IFN有反应的患者中出现。这些结果支持IFN介导的对HCV的抗病毒作用迅速发展,并支持IFN的治疗效果取决于肝脏组织病理学以及HCV RNA滴度和基因型。